Get the Stockscreener App
0.598
4.55%
0.026
Pre-market:
.61
0.012
+2.01%
Sangamo Therapeutics Inc stock is traded at $0.598, with a volume of 4.47M.
It is up +4.55% in the last 24 hours and down -11.20% over the past month.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
See More
Previous Close:
$0.572
Open:
$0.5806
24h Volume:
4.47M
Relative Volume:
0.87
Market Cap:
$180.42M
Revenue:
$52.29M
Net Income/Loss:
$-134.84M
P/E Ratio:
-0.7973
EPS:
-0.75
Net Cash Flow:
$-117.11M
1W Performance:
-5.57%
1M Performance:
-11.20%
6M Performance:
-22.55%
1Y Performance:
-64.82%
1-Day Range:
$0.5745
$0.6219
1-Week Range:
$0.562
$0.6689
52-Week Range:
$0.4111
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
(510) 970-6000
Address
501 CANAL BLVD., RICHMOND, CA
Compare SGMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.598 | 172.58M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Upgrade | Truist | Hold → Buy |
| Dec-10-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-21 | Resumed | Guggenheim | Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Dec-16-20 | Resumed | H.C. Wainwright | Buy |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | SunTrust | Buy |
| Aug-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Jun-20-18 | Initiated | BofA/Merrill | Buy |
| Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Oct-23-15 | Resumed | Jefferies | Buy |
| May-03-13 | Initiated | BioLogic Equity Research | Sell |
| Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
| Jul-29-10 | Reiterated | Wedbush | Outperform |
| Oct-19-09 | Initiated | Brean Murray | Sell |
| Oct-07-09 | Reiterated | Leerink Swann | Outperform |
| Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
Is Sangamo Therapeutics Inc. stock a safe haven assetJuly 2025 Selloffs & Weekly Watchlist for Consistent Profits - newser.com
Will Sangamo Therapeutics Inc. stock outperform Nasdaq indexWeekly Trend Report & Low Drawdown Momentum Ideas - newser.com
How Sangamo Therapeutics Inc. stock reacts to bond yieldsQuarterly Trade Summary & Verified Momentum Stock Ideas - newser.com
Using AI based signals to follow Sangamo Therapeutics Inc.Market Trend Review & Safe Capital Preservation Plans - newser.com
Detecting price anomalies in Sangamo Therapeutics Inc. with AIJuly 2025 Decliners & Free Daily Entry Point Trade Alerts - newser.com
What machine learning models say about Sangamo Therapeutics Inc.Profit Target & AI Based Trade Execution Alerts - newser.com
Sangamo Therapeutics Inc. stock chart pattern explainedMarket Activity Summary & Daily Entry Point Trade Alerts - newser.com
How Sangamo Therapeutics Inc. (GBY) stock reacts to monetary easingJuly 2025 Outlook & Stepwise Entry/Exit Trade Alerts - newser.com
Real time pattern detection on Sangamo Therapeutics Inc. stockEarnings Risk Summary & Precise Entry and Exit Recommendations - newser.com
Is Sangamo Therapeutics Inc. stock in correction or buying zoneMarket Growth Report & Smart Allocation Stock Tips - newser.com
Published on: 2025-10-31 05:14:43 - newser.com
How hedge fund analytics apply to Sangamo Therapeutics Inc. stock2025 Earnings Surprises & Stepwise Trade Signal Guides - newser.com
Why retail investors favor Sangamo Therapeutics Inc. stockJuly 2025 Chart Watch & Reliable Momentum Entry Alerts - newser.com
What analyst consensus says on Sangamo Therapeutics Inc. stockTrade Risk Report & Fast Exit/Entry Strategy Plans - newser.com
What analysts say about Sangamo Therapeutics Inc stockEarnings Per Share Trends & Big Returns, Small Investment – Learn How - earlytimes.in
Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call - The Manila Times
We're Hopeful That Sangamo Therapeutics (NASDAQ:SGMO) Will Use Its Cash Wisely - Yahoo Finance
Published on: 2025-10-29 21:25:18 - newser.com
Sangamo Biosciences Granted Nasdaq Compliance Extension - TipRanks
Published on: 2025-10-27 19:21:18 - newser.com
Will Sangamo Therapeutics Inc. stock gain from strong economyRate Cut & Free Real-Time Market Sentiment Alerts - Fundação Cultural do Pará
Market Recap: How Sangamo Therapeutics Inc. (GBY) stock reacts to monetary easingWeekly Trade Summary & Real-Time Stock Price Movement Reports - Fundação Cultural do Pará
Published on: 2025-10-27 08:50:01 - newser.com
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):